

Renal Pelvis, Ureter, Bladder, and Other Urinary Multiple Primary Rules – Matrix
C659, C669, C670-C679, C680-C689
(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.
 ** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

Rule	Site	Histology	Timing	Behavior	Notes/Examples	Primary
UNKNOWN IF SINGLE OR MULTIPLE TUMORS					Tumor(s) not described as metastasis	
M1					Use this rule only after all information sources have been exhausted.	Single*
SINGLE TUMOR					1: Tumor not described as metastasis 2: Includes combinations of in situ and invasive	
M2	Single				The tumor may overlap onto or extend into adjacent/contiguous site or subsite	Single*
MULTIPLE TUMORS Multiple tumors may be a single or multiple primaries					1: Tumors not described as metastases 2: Includes combinations of in situ and invasive	
M3	When no other urinary sites are involved, tumor(s) in the right renal pelvis and tumor(s) the left renal pelvis				Use this rule and abstract as a multiple primary unless documented to be metastatic.	Multiple**
M4	When no other urinary sites are involved, tumor(s) in the right ureter and tumor(s) in the left ureter				Use this rule and abstract as a multiple primary unless documented to be metastatic.	Multiple**
M5			More than 60 days after diagnosis	An invasive following an in situ	1: The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. 2: Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease.	Multiple**

Urinary MP

**Renal Pelvis, Ureter, Bladder, and Other Urinary Multiple Primary Rules – Matrix
C659, C669, C670-C679, C680-C689**

(Excludes lymphoma and leukemia M9590-9989 and Kaposi sarcoma M9140)

Rule	Site	Histology	Timing	Behavior	Notes/Examples	Primary
M6	Bladder	Any combination of: <ul style="list-style-type: none"> • Papillary carcinoma (8050) or • Transitional cell carcinoma (8120-8124) or • Papillary transitional cell carcinoma (8130-8131) 				Single*
M7			More than three (3) years apart			Multiple**
M8	Two or more of the following sites <ul style="list-style-type: none"> • Renal pelvis (C659) • Ureter(C669) • Bladder (C670-C679) • Urethra /prostatic urethra (C680) 	Urothelial tumors (See Table 1)*				Single*
M9		Tumors with histology codes different at the first (x <u>xxx</u>), second (x <u>xxx</u>), or third (xx <u>xx</u>) number				Multiple**
M10	Tumors with topography codes different at the second (C <u>x</u> xx) and/or third (Cxx <u>x</u>) character					Multiple**
M11	Does not meet any of the above criteria				When an invasive tumor follows an in situ tumor within 60 days, abstract as a single primary.	Single*